The nurse is assessing the client and notes on physical exam that the client has an enlarged forehead and protruding jaw. The nurse suspects that the client is experiencing:
1. gigantism.
2. deficient ADH.
3. acromegaly.
4. hypopituitarism.
Answer: 3
1. Gigantism occurs when the pituitary gland over-secretes growth hormone during childhood and the long bones grow, producing an abnormally tall adult.
2. Deficient ADH produces SIADH and is secreted by the posterior pituitary gland.
3. Acromegaly is a hypersecretion of growth hormone in the adult. Since the epiphyseal plates of the bones close in adolescence, the adult client experiences a thickening and enlarging of bones and connective tissue.
4. Symptoms of hypopituitarism will depend on which hormone is under-producing and when in the lifecycle the alteration occurs. Acromegaly is hypersecretion of growth hormone.
You might also like to view...
A patient returns from a trip to the Caribbean and is suffering from severe diarrhea related to E. coli. Which of the following medications is the drug of choice for traveler's diarrhea?
A) Rifaximin (Xifaxan) B) Spectinomycin (Trobicin) C) Chloramphenicol (Chloromycetin) D) Erythromycin (Ery-Tab)
The nurse is completing an admission physical assessment on a client diagnosed with obsessive-compulsive disorder. Which of the following would be considered objective data?
A) Medical history B) Thoughts C) Present symptoms D) Client self-report
The nurse is performing a focused interview with a client who was recently diagnosed with varicose veins. Which of the following statements by the client are associated with risk factors for varicose veins? Standard Text: Select all that apply
1. "My mother had big veins on her legs from the time I was little.". 2. "My father is of Japanese descent.". 3. "I'm a hair stylist.". 4. "I was pregnant once and have a son.". 5. "I know I weigh a lot more than I should.".
The rationale for the 1992 changes in the Food and Drug Administration regulations to permit accelerated approval of drugs for the treatment of life-threatening or severely debilitating disease was:
A. to allow for marketing before completion of Phase II of drug trials. B. to ensure that the unknown risks associated with early approval are balanced by the need for effective drugs. C. to change the rules because existing FDA regulations were too stringent for potentially effective drugs. D. to accelerate approval of new drugs to give physicians the option of using them without research findings.